Advertisement Xencor begins XmAb5871 Phase 1 Study to treat autoimmune diseases - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Xencor begins XmAb5871 Phase 1 Study to treat autoimmune diseases

Xencor has commenced the Phase 1 clinical trial of XmAb5871, a therapeutic antibody used to treat autoimmune diseases like Lupus and Rheumatoid Arthritis

XmAb5871, a humanized monoclonal antibody using selective dual-targeting mechanism for B cell inhibition by targeting the antigen CD19 and co-engaging CD32b (Fc?RIIb), helps in suppression of autoimmune response.

Preclinical studies demonstrated that XmAb5871 suppresses autoimmune response in humanized mouse models of systemic lupus erythematosus (SLE), without the depletion of B cells.

The endpoints of the Phase 1 study are safety, pharmacokinetics and a number of biomarkers of immunomodulatory drug activity.